These benefits are reflected in the clinical guidelines published by the American Diabetes Association (ADA) and the American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE), which recommend use of a GLP-1RA or a sodium-glucose co-transporter-2 inhibitor (SGLT2i) with demonstrated CV risk reduction in patients with established/high risk of atherosclerotic CVD (ASCVD), while considering patient-specific factors [15, 17]
1H), and progressive motility (48.750 11.810 vs
Likewise, a medication that combines conjugated estrogens with the estrogen agonist/antagonist bazedoxifene is approved to prevent, not treat, osteoporosis after menopause, as well as to treat moderate to severe vasomotor symptoms
To identify specific and abundant signatures of adult enterocytes, pseudobulk differential expression analysis was conducted using DESeq2
For PS exposure measure, gating was set using data obtained with nave erythrocytes DMSO control
Halabe A, Sperling O